89bio Inc
ETNB
Company Profile
Business description
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
Contact
655 Montgomery Street
Suite 1500
San FranciscoCA94111
USAT: +1 415 432-9270
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
93
Stocks News & Analysis
stocks
Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?
With the monetization of GenAI, here’s what we think of Alphabet’s stock
stocks
Going into earnings, Is Meta stock a buy, a sell, or fairly valued?
With a focus on leveraging its AI investments, here’s what we think of Meta stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,946.20 | 20.00 | 0.22% |
| CAC 40 | 7,798.22 | 24.45 | -0.31% |
| DAX 40 | 24,307.80 | 18.29 | 0.08% |
| Dow JONES (US) | 44,323.07 | 19.12 | -0.04% |
| FTSE 100 | 9,012.99 | 20.87 | 0.23% |
| HKSE | 25,014.60 | 20.46 | 0.08% |
| NASDAQ | 20,974.18 | 78.52 | 0.38% |
| Nikkei 225 | 39,902.05 | 82.94 | 0.21% |
| NZX 50 Index | 12,831.27 | 130.24 | -1.00% |
| S&P 500 | 6,305.60 | 8.81 | 0.14% |
| S&P/ASX 200 | 8,684.60 | 16.40 | 0.19% |
| SSE Composite Index | 3,559.17 | 0.62 | -0.02% |